Tuesday, April 12, 2022 3:12:59 AM
CAR-Ts have revolutionised the treatment of some blood cancers like B cell lymphomas, but have been largely unsuccessful at targeting solid tumours, in part as the cells do not penetrate tumour tissue as effectively as the bone marrow.
BioNTech’s answer to that is to combine an autologous (patient-derived) CAR-T with a tumour-targeted mRNA vaccine that codes for the CAR-T target antigen, attempting to both amplify the response to the cell therapy and stimulate a response by the patient’s immune system.
In a phase 1/2 trial reported at the American Association of Cancer Research (AACR) congress, there were preliminary signs that the approach could work.
BioNTech said its CAR-T (BNT211) and mRNA vaccine (CarVAC) combination – both targeting the cancer-associated antigen claudin-6 – was shown to be safe and well-tolerated in a group of 16 solid tumour patients, with preliminary signs of efficacy.
Patients received the CAR-T alone at ascending doses in the first part of the trial, moving on to combination use with the mRNA vaccine afterwards. It is too soon to see if the combination is working better, but the first results indicate that targeting claudin-6 in patients is a valid strategy to pursue.
Six of 14 evaluable patients with testicular or ovarian cancer achieved a partial response six weeks after treatment, a rate of 43%, with four of the responders getting the CAR-T on its own, while two were also treated with the mRNA shot.
Another five subjects in the study – which also included patients with endometrial cancer, fallopian tube cancer, sarcoma, and gastric cancer – had stable disease and shrinking of some target cancer lesions, giving an overall disease control rate of 86%.
The researcher presenting the data at AACR, John Haanen of the Netherlands Cancer Institute, said there was evidence of a “deepening and durability” of the tumour responses over time. With one patient achieving a complete response after 18 weeks. On the other hand, there was also evidence of the treatment effect wearing off in some patients.
“Claudin-6 was never targeted with cellular therapy before, but in this study, the approach is already showing an efficacy that may be better than the data from other CAR-T trials in solid tumours,” he said.
The treatment had manageable side effects, including cases of cytokine release syndrome (CRS) – a known hazard of CAR-T therapy – that resolved after treatment with Roche’s anti-inflammatory drug Actemra (tocilizumab).
Additional data from the ongoing trial will be available later this year, said BioNTech, currently riding high on the success of its COVID-19 vaccine.
BNTX $$$$
Recent BNTX News
- Anglo American Rejects BHP Group’s Offer, Toyota Invests $1.4 Billion in Indiana, and More News • IH Market News • 04/26/2024 11:48:07 AM
- Coca-Cola and Microsoft Sign Billion-Dollar Agreement, Apple Event Set for May 7, and More News • IH Market News • 04/24/2024 11:28:02 AM
- BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024 • GlobeNewswire Inc. • 04/22/2024 10:45:00 AM
- Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer • GlobeNewswire Inc. • 04/07/2024 06:00:00 PM
- Apple Pre-Market Drop Due to Antitrust Threats, Surprising Profit Boosts Micron Shares, and Latest Market Updates • IH Market News • 03/21/2024 11:17:26 AM
- U.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices Dip • IH Market News • 03/20/2024 11:17:32 AM
- BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 03/20/2024 10:15:00 AM
- BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer • GlobeNewswire Inc. • 03/20/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 01:04:00 PM
- BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024 • GlobeNewswire Inc. • 03/11/2024 11:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 12, 2024 in BioNTech Lawsuit - BNTX • PR Newswire (US) • 03/11/2024 10:25:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 01:41:50 PM
- BioNTech Announces Planned Retirement of Sean Marett • GlobeNewswire Inc. • 03/07/2024 11:45:00 AM
- BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024 • GlobeNewswire Inc. • 03/06/2024 11:45:00 AM
- The Gross Law Firm Reminds BioNTech SE Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 12, 2024 - BNTX • PR Newswire (US) • 03/05/2024 10:45:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 11:26:07 PM
- Shareholders that lost money on BioNTech SE(BNTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 02/26/2024 10:45:00 AM
- BioNTech SE Sued for Securities Law Violations - Contact The Gross Law Firm Before March 12, 2024 to Discuss Your Rights - BNTX • PR Newswire (US) • 02/22/2024 10:45:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/15/2024 09:10:24 PM
- Shareholders that lost money on BioNTech SE(BNTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 02/15/2024 10:00:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:26:25 PM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of BioNTech SE(BNTX) Shareholders • PR Newswire (US) • 02/09/2024 10:45:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/08/2024 11:08:22 AM
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs • GlobeNewswire Inc. • 02/08/2024 10:45:00 AM
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs • GlobeNewswire Inc. • 02/08/2024 10:45:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM